Influenza a (H1N1) Virus Resistance to Cyanovirin-N Arises Naturally during Adaptation to Mice and by Passage in Cell Culture in the Presence of the Inhibitor
暂无分享,去创建一个
M. Boyd | D. Smee | L. Gubareva | V. Mishin | M. Wandersee | B. O’Keefe | C. Saucedo | Carrie J. Saucedo | Melissa B Checketts
[1] R. Shattock,et al. High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. , 2007, Virology.
[2] B. Bosch,et al. The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins , 2007, The Journal of antimicrobial chemotherapy.
[3] David E. Swayne,et al. A Two-Amino Acid Change in the Hemagglutinin of the 1918 Influenza Virus Abolishes Transmission , 2007, Science.
[4] F. Gago,et al. Mutational Pathways, Resistance Profile, and Side Effects of Cyanovirin Relative to Human Immunodeficiency Virus Type 1 Strains with N-Glycan Deletions in Their gp120 Envelopes , 2006, Journal of Virology.
[5] H. Klenk,et al. Polymer-bound 6' sialyl-N-acetyllactosamine protects mice infected by influenza virus. , 2005, Antiviral research.
[6] Vasiliy P. Mishin,et al. Effect of Hemagglutinin Glycosylation on Influenza Virus Susceptibility to Neuraminidase Inhibitors , 2005, Journal of Virology.
[7] E. Hoffmann,et al. A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. , 2005, Virology.
[8] D. Smee,et al. Experimental disease models of influenza virus infections: recent developments , 2004 .
[9] Y. Muraki,et al. Effect of the Addition of Oligosaccharides on the Biological Activities and Antigenicity of Influenza A/H3N2 Virus Hemagglutinin , 2004, Journal of Virology.
[10] K. Gustafson,et al. Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin , 2003, Antimicrobial Agents and Chemotherapy.
[11] Mike Bray,et al. Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.
[12] M. Hart,et al. Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannose-binding lectin. , 2003, The Journal of general virology.
[13] S. Baird,et al. Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: Identification of functional themes , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] M. Boyd,et al. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. , 2001, Molecular pharmacology.
[15] M. Boyd,et al. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. , 2001, The Journal of pharmacology and experimental therapeutics.
[16] D. Smee,et al. Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities , 2001, Antimicrobial Agents and Chemotherapy.
[17] M. Boyd,et al. Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. , 2000, Molecular pharmacology.
[18] K. Zaner,et al. Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity. , 2000, The Biochemical journal.
[19] E. Govorkova,et al. Amino acid changes in the hemagglutinin and matrix proteins of influenza a (H2) viruses adapted to mice. , 2000, Acta virologica.
[20] E. Brown,et al. Genetic analysis of mouse-adapted influenza A virus identifies roles for the NA, PB1, and PB2 genes in virulence. , 1999, Virus research.
[21] L. Pannell,et al. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. , 1998, Protein expression and purification.
[22] L. Morey,et al. Collectin-mediated antiviral host defense of the lung: evidence from influenza virus infection of mice , 1997, Journal of virology.
[23] L K Pannell,et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.
[24] P. Reading,et al. Changes in the hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence for mice , 1997, Archives of Virology.
[25] D. Jackson,et al. Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[26] S. Fields,et al. Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype , 1981, Nature.
[27] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .